You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."
The company hopes to help consumer genomics firms and healthcare companies reduce the IT burdens associated with launching a new test.
The fledgling company, started as a promise to the founder's dying sister, is trying to succeed in a consumer niche where so many others have failed.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.
The company will use the funding to market its GoodCell Diagnostics service, which combines genetic testing and personally controlled biobanking.
The clinical decision support content developer is integrating genetic testing information into its knowledgebase to assist physicians at the point of care.
Despite the step-up in FDA action against labs offering PGx tests, the success of these programs suggests that access to them isn't being stifled as some feared.
The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.